ESC Premium Access

Worsening of renal function in atrial fibrillation patients with stage 3 or 4 chronic kidney disease treated with warfarin or rivaroxaban - evidence from the real-world CALLIPER study in the US claims

Congress Session

About the speaker

Doctor Tatsiana Vaitsiakhovich

Bayer AG, Berlin (Germany)
0 follower

13 more presentations in this session

Oral anticoagulants and their effect on kidneys function, is warfarin safe?

Speaker: Associate Professor T. Novikova (Saint Petersburg, RU)

Thumbnail

Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in newly diagnosed non-valvular atrial fibrillation.

Speaker: Doctor L. Bergamaschi (Bologna, IT)

Thumbnail

Inappropriate dosing of non-vitamin K oral anticoagulants (NOACs) in atrial fibrillation patients in Europe

Speaker: Ms I. Palau (London, GB)

Thumbnail

Patients with atrial fibrillation exhibit a systemic prothrombotic state attributable to impaired endogenous fibrinolysis

Speaker: Doctor Y. Gue (Liverpool, GB)

Thumbnail

Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study

Speaker: Professor P. Hjemdahl (Stockholm, SE)

Thumbnail

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 1

Speakers: Doctor T. Vaitsiakhovich, Associate Professor T. Novikova, Doctor L. Bergamaschi, Ms I. Palau, Doctor Y. Gue...
Thumbnail

About the event

Image

ESC CONGRESS 2019

31 August - 4 September 2019

Sessions Presentations

This platform is supported by

logo Novo Nordisk